Another breakthrough in the field of diabetes, Chinese experts leading once again
Recently, China has made significant breakthroughs in the field of diabetes. Professor Deng Hongkui from Peking University successfully cured a 14-year-old type 1 diabetes patient with stem cell therapy. The phase 2 study led by Professor Zhu Dalong from Nanjing Drum Tower Hospital, which is globally leading in biased GLP-1 diabetes research, has shown significant effectiveness of exenatide in lowering HbA1c levels and weight. This drug is the world's first domestically produced innovative GLP-1 biased drug, expected to be approved for market launch by the end of next year or early the year after, bringing new treatment options for diabetes patients
Recent breakthroughs have been made in the field of diabetes in China. Professor Deng Hongkui from Peking University used stem cell therapy to cure a patient with a 14-year history of type 1 diabetes, bringing hope to patients who have long been troubled by chronic injections.
Today, more good news comes from Chinese endocrinology experts. Professor Zhu Dalong from Nanjing Drum Tower Hospital led a globally leading phase 2 study on a selective GLP-1 agonist for diabetes, which was published in the sub-journal "Nature Communication" of Nature. The study results showed that after 20 weeks of monotherapy with Inoglucaide, three dosage groups were significantly effective compared to the placebo group. In the 1.2mg treatment group, the key indicator of diabetes control, HbA1c level, could be reduced by up to 2.39%, and patients receiving treatment also experienced significant weight loss.
The drug used in this study is the world's first selective GLP-1 domestically produced innovative drug - Inoglucaide. The key registration studies led by DaSheng Bio have been completed, and this publication in the sub-journal of Nature is the result of its phase 2 study. The results of Inoglucaide in diabetes treatment have been presented at international diabetes conferences in the United States and Europe. Phase 3 studies have shown that 1.2mg of Inoglucaide can reduce glycosylated hemoglobin by up to 2.43%, and there are significant improvements in postprandial blood sugar, blood lipids, weight, fatty liver, and other indicators. In recent years, the popularity of the diabetes and weight-loss drug Semaglutide has been increasing. Inoglucaide is a completely domestically developed new drug with the same mechanism. Unlike Semaglutide, Inoglucaide has better weight loss effects and a higher weight loss response rate for more people.
Professor Zhu Dalong stated: "I am pleased to see the publication of the research results of Inoglucaide in the sub-journal of Nature. This is the first phase 2 registration study result of a selective GLP-1 molecule in global research. Its superior efficacy may become a more suitable choice for Chinese patients. We will have more research results to share with everyone in the future."
It is reported that this domestically developed original innovative drug is expected to be approved for market as early as the end of next year or the beginning of the year after. At that time, diabetic patients will be able to control their blood sugar with a once-a-week monotherapy, bringing good news to the obese population.
Keyword: Innovent Biologics